Haisco Pharmaceutical Group Co. Ltd
- Biotech or pharma, therapeutic R&D
Haisco Pharmaceutical Group is a leading fully integrated pharmaceutical companyin China, publicly traded on the Shenzhen Stock Exchange (SZEX: 002653) with a market capitalization of ~ $6 billion.
With a dedicated in-house R&D team of 800+ scientists and three proprietary technology platforms—Targeted Protein Degradation, Small Molecule Drug Discovery, and Inhalation Delivery Systems—Haisco has built a robust pipeline of 20+ novel chemical entities (NCEs). These programs target high-need therapeutic areas, including:
Central Nervous System (CNS), Oncology, Respiratory Diseases, Immunology, Metabolic Disorders
Haisco’s innovation has attracted global partnerships:
- Out-licensing of a TYK2 inhibitor to Alumis (Nasdaq: ALMS), which subsequently secured $210 million in funding and achieved a successful Nasdaq IPO.
- Exclusive worldwide rights (ex-China) for a DPP1 inhibitor in respiratory diseases granted to Chiesi Group, underscoring Haisco’s leadership in respiratory therapeutics
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}